P38 PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE PHASE 3 OCEAN STUDY

• F Schjesvold,
• H Ludwig,
• S Delimpasi,
• P Robak,
• M Mateos,
• A Sandberg,
• M Thuresson,
• S Norin,
• P Richardson,
• P Sonneveld

Affiliations

F Schjesvold

1 Oslo Myeloma Center, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway

H Ludwig

2 Department of Medicine I, Center for Medical Oncology and Hematology with Outpatient Department and Palliative Care, Wilhelminen Cancer Research Institute, Vienna, Austria

S Delimpasi

3 Bone Marrow Transplantation Unit and Department of Hematology, Evangelismos Hospital, Athens, Greece

P Robak

4 Department of Hemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic

M Mateos

5 Hospital Clínico Universitario de Salamanca/IBSAL/CIC, Salamanca, Spain

A Sandberg

6 Oncopeptides AB, Stockholm, Sweden

M Thuresson

6 Oncopeptides AB, Stockholm, Sweden

S Norin

6 Oncopeptides AB, Stockholm, Sweden

P Richardson

7 Dana-Farber Cancer Institute, Boston, MA, USA

P Sonneveld

8 Erasmus MC Cancer Institute, Rotterdam, the Netherlands